Published in J Neurosci on July 14, 2004
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol (2013) 1.19
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
Immunotherapy for Alzheimer's disease. Biochem Pharmacol (2014) 1.04
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Mol Ther (2008) 1.02
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology (2011) 1.02
Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets (2009) 0.98
MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice. J Neurosci (2013) 0.98
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct (2009) 0.95
Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol (2007) 0.93
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Immunotherapy for tauopathies. J Mol Neurosci (2011) 0.92
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine (2008) 0.90
Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. J Neuroinflammation (2006) 0.90
Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics (2008) 0.90
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
Antibodies as defensive enzymes. Springer Semin Immunopathol (2005) 0.89
Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. PLoS One (2009) 0.88
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol Aging (2013) 0.84
Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome Sci (2014) 0.83
Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. DNA Cell Biol (2006) 0.82
Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines (2010) 0.80
Could immunomodulation be used to prevent prion diseases? Expert Rev Anti Infect Ther (2012) 0.80
Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. J Alzheimers Dis (2009) 0.80
AD vaccines: conclusions and future directions. CNS Neurol Disord Drug Targets (2009) 0.79
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2010) 0.78
Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms. Front Aging Neurosci (2015) 0.78
Current experimental therapy for Alzheimer's disease. Curr Neuropharmacol (2007) 0.76
Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Curr Neuropharmacol (2011) 0.76
Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell Mol Neurobiol (2009) 0.76
Transgenic rice expressing amyloid β-peptide for oral immunization. Int J Biol Sci (2011) 0.76
Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi (2014) 0.75
Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice. Acta Neuropathol Commun (2015) 0.75
Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice. Front Endocrinol (Lausanne) (2016) 0.75
Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation. Vaccines (Basel) (2014) 0.75
Antibody Therapeutics Targeting Aβ and Tau. Cold Spring Harb Perspect Med (2017) 0.75
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A (2005) 3.91
A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J (2002) 3.87
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci (2007) 3.10
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
A primer of amyloid nomenclature. Amyloid (2007) 2.70
The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol (2010) 2.42
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J (2007) 1.97
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs. Microsc Res Tech (2005) 1.85
The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem (2005) 1.67
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Circadian gene expression is resilient to large fluctuations in overall transcription rates. EMBO J (2008) 1.61
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol (2009) 1.57
Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol (2003) 1.56
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet (2008) 1.49
Controlled exchange of chromosomal arms reveals principles driving telomere interactions in yeast. Genome Res (2007) 1.48
BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem (2005) 1.48
Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus. Blood (2010) 1.47
Circadian clock characteristics are altered in human thyroid malignant nodules. J Clin Endocrinol Metab (2013) 1.47
Multiresolution monogenic signal analysis using the Riesz-Laplace wavelet transform. IEEE Trans Image Process (2009) 1.47
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem (2007) 1.44
Complex wavelets for extended depth-of-field: a new method for the fusion of multichannel microscopy images. Microsc Res Tech (2004) 1.43
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
Effect of aging on elastin functionality in human cerebral arteries. Stroke (2009) 1.40
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
Physostigmine reverses cognitive dysfunction caused by moderate hypoxia in adult mice. Anesth Analg (2007) 1.38
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Sporadic and familial cerebral amyloid angiopathies. Brain Pathol (2002) 1.33
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem (2004) 1.30
Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging (2004) 1.27
Immunization delays the onset of prion disease in mice. Am J Pathol (2002) 1.26
Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J Biol Chem (2004) 1.26
Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis (2002) 1.24
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
Lung tissue classification using wavelet frames. Conf Proc IEEE Eng Med Biol Soc (2007) 1.22
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
Predicting stem cell fate changes by differential cell cycle progression patterns. Development (2012) 1.21
Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. J Biol Chem (2005) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Copper chelation delays the onset of prion disease. J Biol Chem (2003) 1.17
Axonal transport of British and Danish amyloid peptides via secretory vesicles. FASEB J (2003) 1.17
Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol (2002) 1.16
Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (2007) 1.15
Amyloidosis and Alzheimer's disease. Adv Drug Deliv Rev (2002) 1.14
Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis (2001) 1.11
Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res (2004) 1.11
Morphological and functional abnormalities in mitochondria associated with synaptic degeneration in prion disease. Am J Pathol (2010) 1.09
Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett (2003) 1.09
Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res (2004) 1.08
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem (2003) 1.07
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol (2002) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target (2002) 1.06
CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol (2007) 1.06
Depressive behavior in mice due to immune stimulation is accompanied by reduced neural activity in brain regions involved in positively motivated behavior. Biol Psychiatry (2006) 1.05
Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol (2005) 1.05
Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol (2013) 1.04
Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem (2002) 1.04
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol (2012) 1.02
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol (2004) 1.01
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol (2006) 1.01
Greater risk of Alzheimer's disease in older adults with insomnia. J Am Geriatr Soc (2011) 1.01
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol (2008) 1.00
Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis (2009) 1.00
Clusterin and Alzheimer's disease. Subcell Biochem (2005) 1.00
Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol (2010) 0.99
The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.99
Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice. J Virol (2008) 0.99
Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage (2011) 0.98
Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease. J Virol (2005) 0.95